Table 3

Antioxidant enzyme activity and lipid peroxidation before and after intervention
Placebo (n = 19) Low-dose (n = 19) High-dose (n = 19)
SOD activity (U/ml)
 Pre-treatment 12.6±0.97 10.1±0.68 11.9±0.98
 Post-treatment 12.2±0.96 12.1±1.03* 14.2±1.15*
 Change −0.46±0.57 1.95±0.80 2.24±0.86
GPx activity (nmol/min/ml)
 Pre-treatment 41.1±3.71 34.3±1.88 34.9±2.53
 Post-treatment 39.1±3.72 37.4±2.27 43.5±2.53**
 Change −2.00±2.08 3.05±2.15 8.66±2.63
Catalase (nmol/min/ml)
 Pre-treatment 103.2±11.5 94.5±8.56 86.9±11.7
 Post-treatment 99.0±13.2 118.3±11.8 135.5±12.3**
 Change −4.17±12.4 23.8±12.4 48.5±12.3
8-epi-PGF (pg/mg creatinine)a)
 Pre-treatment 1450.3±103.7 1519.0±222.3 1516.3±105.9
 Post-treatment 1641.6±136.5 1323.4±106.6 1383.5±120.2
 Change 191.3±107.7 −195.6±147.6 −132.8±127.9

SOD, superoxide dismutase; GPx, glutathione peroxidase; 8-epi-PGF, 8-epi-prostaglandin F.

a)Tested after logarithmic transformation.

Results are expressed as standard error of the mean (SEM).

Tested by Wilcoxon signed-rank test or analysis of covariance (ANCOVA) using a general linear model (GLM) with adjustments for age, sex, BMI, smoking, drinking, systolic BP, diastolic BP, and baseline values.

*P <0.05,**P <0.01 compared with the baseline in each group; P <0.05, ††P <0.01 compared with the placebo group.

Kim et al.

Kim et al. Nutrition Journal 2012 11:47   doi:10.1186/1475-2891-11-47

Open Data